Thank you very much, Chair.
Despite what Mr. Julian wants to portray, this is after considerable consultation with the legislative counsel to understand the terminology. That was a question we had. It's not something that, unlike the NDP, we just dreamed up on the back of a napkin yesterday and tried to bring forward here or through a table-dropped amendment. I take great umbrage at his ridiculous notion that this is something that was not well thought out or actually consulted upon. That's an absolutely ridiculous accusation and something that I wish didn't bear a response, but it does, because of the ridiculous and unwarranted nature of his inflammatory comments, which I can only believe are intended to be inflammatory in this context.
In spite of that, if everybody else around this table is convinced that this is not the appropriate reference, I'm quite happy to seek unanimous consent to withdraw it. As I said, this is based on the legal counsel we obtained from the House of Commons. It's not like we went out and sought separate legal counsel for this; this is the actual counsel we received, and therefore we believed it was important to do it. This is not meant to be contentious or perhaps, as Mr. Julian is thinking, part of a filibuster. This is meant to be inclusive of all the appropriate people who had come to the table who potentially can be impacted by the pharmacare pamphlet.
In your terminology, Chair, if it's the will of the room to say that in spite of the good counsel that I believe we received, this is not a helpful amendment, I'm happy to seek unanimous consent to withdraw it.